Skip to main content

Advertisement

Clinical/Translational Cancer Immunotherapy

Section edited by James L. Gulley, MD, PhD and Douglas G. McNeel, MD, PhD

First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.

Page 1 of 5

  1. Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomi...

    Authors: Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:309

    Content type: Research article

    Published on:

  2. Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stim...

    Authors: Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason G. Sagert, William T. Curry, Bob S. Carter…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:304

    Content type: Short report

    Published on:

  3. Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-de...

    Authors: Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:302

    Content type: Research article

    Published on:

  4. Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear.

    Authors: Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:299

    Content type: Research article

    Published on:

  5. Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically act...

    Authors: Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:292

    Content type: Research article

    Published on:

  6. The peculiar multiple myeloma microenvironment, characterized by up-regulated levels of several inflammatory chemokines, including the CXCR3 receptor ligands CXCL9 and CXCL10, limits NK cell positioning into t...

    Authors: Valentina Bonanni, Fabrizio Antonangeli, Angela Santoni and Giovanni Bernardini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:290

    Content type: Research article

    Published on:

  7. The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce.

    Authors: Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri and Quoc-Dien Trinh

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:289

    Content type: Research article

    Published on:

  8. The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required.

    Authors: Gareth D. Healey, Belen Pan-Castillo, Jezabel Garcia-Parra, Julia Davies, Shaun Roberts, Eilir Jones, Kalyan Dhar, Sarika Nandanan, Nasima Tofazzal, Luke Piggott, Richard Clarkson, Gillian Seaton, Asa Frostell, Tim Fagge, Colin McKee, Lavinia Margarit…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:280

    Content type: Research article

    Published on:

  9. Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus s...

    Authors: Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:277

    Content type: Research article

    Published on:

  10. Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794),...

    Authors: Indu Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts, Daniel Nunez, Gareth Betts, Natalie Bath, Alex J. Tipping, Luca Melchiori, Jean-Marc Navenot, John Glod, Crystal L. Mackall, Sandra P. D’Angelo, Dejka M. Araujo, Warren A. Chow…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:276

    Content type: Research article

    Published on:

  11. Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN ...

    Authors: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:275

    Content type: Research article

    Published on:

  12. Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, an...

    Authors: Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse and Kun Cheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:270

    Content type: Research article

    Published on:

  13. Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmu...

    Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:269

    Content type: Research article

    Published on:

  14. The tumor microenvironment exists in a state of dynamic equilibrium, in which a balance of agonist and antagonist signals govern the anti-tumor immune responses. Previous studies have shown that chemotherapy c...

    Authors: Tae Heung Kang, Chih-Ping Mao, Young Seob Kim, Tae Woo Kim, Andrew Yang, Brandon Lam, Ssu-Hsueh Tseng, Emily Farmer, Yeong-Min Park and Chien-Fu Hung

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:260

    Content type: Short report

    Published on:

  15. Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in pat...

    Authors: Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:253

    Content type: Research article

    Published on:

  16. Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP f...

    Authors: Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio and Kazuhiko Nakagawa

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:251

    Content type: Research article

    Published on:

  17. Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized anti...

    Authors: Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang and Hang-Ping Yao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:250

    Content type: Research article

    Published on:

  18. PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patient...

    Authors: Fan Luo, Min Luo, Qi-Xiang Rong, Hong Zhang, Zhen Chen, Fang Wang, Hong-Yun Zhao and Li-Wu Fu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:245

    Content type: Research article

    Published on:

  19. Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation m...

    Authors: Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:244

    Content type: Research article

    Published on:

  20. Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the func...

    Authors: Shiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, Astar Shamul, Tilda Barliya and Cyrille J. Cohen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:243

    Content type: Research article

    Published on:

  21. The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity,...

    Authors: Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Tenglong Tang, Mehmet Altan, Anne-Maria P. Chaftari, Pablo C. Okhuysen, Robert R. Jenq and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:242

    Content type: Research article

    Published on:

  22. HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition...

    Authors: Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:240

    Content type: Research article

    Published on:

  23. Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to another ...

    Authors: Hari Menon, Dawei Chen, Rishab Ramapriyan, Vivek Verma, Hampartsoum B. Barsoumian, Taylor R. Cushman, Ahmed I. Younes, Maria A. Cortez, Jeremy J. Erasmus, Patricia de Groot, Brett W. Carter, David S. Hong, Isabella C. Glitza, Renata Ferrarotto, Mehmet Altan, Adi Diab…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:237

    Content type: Research article

    Published on:

  24. T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantige...

    Authors: Qin Tan, Chaoting Zhang, Wenjun Yang, Ying Liu, Palashati Heyilimu, Dongdong Feng, Liying Xing, Yang Ke and Zheming Lu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:232

    Content type: Research article

    Published on:

  25. Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that play an important role in immune evasion, PD-1/PD-L1 inhibitor tolerance and tumour progression. Therefore, MDSCs are potential targets...

    Authors: Wanfeng Gao, Xiaoyun Zhang, Wendong Yang, Daolei Dou, Heng Zhang, Yuanhao Tang, Weilong Zhong, Jing Meng, Yun Bai, Yanrong Liu, Lan Yang, Shuang Chen, Huijuan Liu, Cheng Yang and Tao Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:231

    Content type: Research article

    Published on:

  26. T cell receptor (TCR) gene-engineered T cells have shown promise in the treatment of melanoma and synovial cell sarcoma, but their application to epithelial cancers has been limited. The identification of nove...

    Authors: Bridget Marcinkowski, Sanja Stevanović, Sarah R. Helman, Scott M. Norberg, Carylinda Serna, Benjamin Jin, Nikolaos Gkitsas, Tejas Kadakia, Andrew Warner, Jeremy L. Davis, Lisa Rooper and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:229

    Content type: Short report

    Published on:

  27. Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and mainta...

    Authors: Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang and Leonard T. Heffner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:227

    Content type: Research article

    Published on:

  28. Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune relat...

    Authors: Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:226

    Content type: Short report

    Published on:

  29. The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies.

    Authors: Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:225

    Content type: Research article

    Published on:

  30. As part of the 2018 Immunotherapy Bridge congress (November 28–29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy tod...

    Authors: Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi and Igor Puzanov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:221

    Content type: Review

    Published on:

  31. Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosy...

    Authors: Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki and Ichinosuke Hyodo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:219

    Content type: Research article

    Published on:

  32. Prostate cancer is poorly responsive to immune checkpoint inhibition, yet a combination with radiotherapy may enhance the immune response. In this study, we combined radiotherapy with immune checkpoint inhibit...

    Authors: Stephanie O. Dudzinski, Brent D. Cameron, Jian Wang, Jeffrey C. Rathmell, Todd D. Giorgio and Austin N. Kirschner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:218

    Content type: Research article

    Published on:

  33. Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can res...

    Authors: Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain and Tomoko Freshwater

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:212

    Content type: Research article

    Published on:

  34. Little is known about tumor-associated vasogenic edema in brain metastasis, yet it causes significant morbidity and mortality. Our purpose was to characterize edema in patients treated with anti-PD-1 and to st...

    Authors: Thuy T. Tran, Amit Mahajan, Veronica L. Chiang, Sarah B. Goldberg, Don X. Nguyen, Lucia B. Jilaveanu and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:200

    Content type: Short report

    Published on:

  35. Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, woul...

    Authors: Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston and Jung-Min Lee

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:197

    Content type: Short report

    Published on:

  36. Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or ste...

    Authors: Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:196

    Content type: Research article

    Published on:

  37. Transient CD4+ T cell depletion led to the proliferation of tumor-specific CD8+ T cells in the draining lymph node and increased infiltration of PD-1+CD8+ T cells into the tumor, which resulted in strong anti-tum...

    Authors: Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:195

    Content type: Research article

    Published on:

  38. Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may arg...

    Authors: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen and Stijn L. W. Koolen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:192

    Content type: Research article

    Published on:

  39. Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell ac...

    Authors: David M. Richards, Viola Marschall, Katharina Billian-Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke, Oliver Hill, Christian Gieffers and Meinolf Thiemann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:191

    Content type: Research article

    Published on:

  40. Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-t...

    Authors: A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:189

    Content type: Research article

    Published on:

  41. Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers. However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challeng...

    Authors: Matthew R. Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, Jose Pulido, Laura Evgin and Richard G. Vile

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:188

    Content type: Research article

    Published on:

  42. Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In ...

    Authors: Cormac Cosgrove, Emilia R. Dellacecca, Joost H. van den Berg, John B. Haanen, Michael I. Nishimura, I. Caroline Le Poole and Hans E. N. Bergmans

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:186

    Content type: Hypothesis

    Published on:

  43. We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. D...

    Authors: Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:177

    Content type: Short report

    Published on:

  44. DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune res...

    Authors: Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat and Vincenzo Cerullo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:174

    Content type: Research article

    Published on:

  45. Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor ...

    Authors: Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:170

    Content type: Short report

    Published on:

  46. Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary ...

    Authors: Yeon Ho Choi, Eun Jin Lim, Se Wha Kim, Yong Wha Moon, Kyung Soon Park and Hee-Jung An

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:168

    Content type: Research article

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:211

  47. The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave...

    Authors: Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba and Rom S. Leidner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:165

    Content type: Research article

    Published on:

  48. The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies off...

    Authors: Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:164

    Content type: Research article

    Published on:

  49. Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipo...

    Authors: Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:163

    Content type: Research article

    Published on:

  50. Melanoma is a very aggressive skin tumor that can be cured when diagnosed and treated in its early stages. However, at the time of identification, the tumor is frequently in a metastatic stage. Intensive resea...

    Authors: Lise Pasquet, Elisabeth Bellard, Sophie Chabot, Bostjan Markelc, Marie-Pierre Rols, Justin Teissie and Muriel Golzio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:161

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement